Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuezhikang versus atorvastatin for glucose metabolism in dyslipidemia patients with prediabetes
ChiCTR2200056381Phase 4Not yet recruiting
- Sponsor
- Ruyang Rural Health Centre
- Start
- Nov 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Xuezhikang and atorvastatin in dyslipidemia and prediabetes (2 arms), sponsored by Ruyang Rural Health Centre. Primary endpoint: HbA1c at 24 weeks. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
Xuezhikangatorvastatin
03
Conditions
dyslipidemiaprediabetes
Beyond the preview
Go deeper on ChiCTR2200056381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056381.